Companies › Phoenix Molecular Designs
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PMD-026 Targeted oral agent for metastatic breast cancer | – | Phase 1 | Metastatic Breast Cancer; Myeloid Malignancy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04115306 | PMD-026 | Phase 1 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT07379125 | PMD-026 | Phase 1 | Myeloid Malignancy | Oncology | Dec 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.